2026-08-29T14:55:22Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/170582024-09-21T20:12:23Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16988

00925njm 22002777a 4500 dc Fernández-Fernández, Cristina author Callado, Luis F author Girón, Rocío author Sánchez, Eva author Erdozain, Amaia M author López-Moreno, José Antonio author Morales, Paula author Rodríguez de Fonseca, Fernando author Fernández-Ruiz, Javier author Goya, Pilar author Meana, J Javier author Martín, M Isabel author Jagerovic, Nadine author 2014-02-20 Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two wellknown drugs, ie, rimonabant and fentanyl. The new compounds have been tested for their affinity and functionality regarding CB1 and CB2 cannabinoid and μ opioid receptors. In [(35)S]-GTPγS (guanosine 5'-O-[gamma-thio]triphosphate) binding assays from the post-mortem human frontal cortex, they proved to be CB1 cannabinoid antagonists and μ opioid antagonists. Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems. 10.2147/DDDT.S55045 1177-8881 Drug design, development and therapy http://hdl.handle.net/10668/1607 24591816 http://hdl.handle.net/20.500.12105/17058 Fentanyl Rimonabant Cannabinoid Opioid Behavioral assays Autopsia Cannabinoides Opioides moduladores de los receptores de cannabinoides Encéfalo Interacciones farmacológicas Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results.